At AAA we manufacture a majority of our products and have developed a global manufacturing network with a total of 20 production facilities in 8 countries.
We are vertically integrated and control production from the manufacturing of enriched water to the production of finished molecular nuclear medicine PET and SPECT products.
We have 16 PET production sites strategically positioned close to our customers as well as 2 SPECT production sites, 1 enriched water production site and 1 independent Lu-177 manufacturing business.
All of our manufacturing facilities operate in conformity with current good manufacturing practices, or cGMP. This network provides the basis for our advanced manufacturing capacity, cost-efficient production and organization of reliable product distribution.
Two of our Italian plants, in the Ivrea and Meldola areas, have obtained approval from AIFA to produce lutetium Lu 177 dotatate (Lutathera), qualifying them as the first industrial pharmaceutical laboratories in the world to receive approval from a central authority to produce an injectable nuclear molecular therapeutic product. Our other production sites develop, manufacture and/or sell our other existing products and product candidates, with the bulk of our production consisting of F-18 PET diagnostic products.
Our network has a longstanding track record of supplying high-quality products to over 250 hospitals in Europe every year.
Our production and R&D resources represent what we believe to be one of our key competitive strengths, as they allow us to develop, manufacture and sell therapeutic and diagnostic products in all significant European markets while positioning us as a licensing and manufacturer partner for companies such as GE Healthcare and Eli Lilly that require qualified manufacturers for their existing and new PET products.